- Home
- / Repros Therapeutics
- / Financials
Header placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit.
Repros Therapeutics financials data including stock price, CreditSafe score, income statement, balance sheet, and cash flow.
Revenue
$47 K
FY, 2016
CreditSafe Score
?
Score changed on Jul 24, 2026
Premium Content only available in Craft’s Intelligence Portal
View 30+ financial ratio metrics including price-to-earnings ratio, debt-to-assets ratio, gross profit margin, and more.
Financial ratio metrics help evaluate the financial strength of a company, and help raise red flags that can indicate potential risk, fulfillment challenges, or even possible bankruptcy.
Learn moreFinancial Statements
| USD | FY, 2011 | FY, 2012 | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 |
|---|---|---|---|---|---|---|
| Revenue | 2.0K | 3.0K | 9.0K | 9.0K | 11.0K | 47.0K |
| Revenue growth, % | 22.2% | -54.5% | ||||
| General and administrative expense | 3.8M | 4.8M | 4.8M | 5.4M | 5.1M | 4.6M |
| Operating expense total | 12.5M | 18.2M | 28.5M | 32.5M | 29.2M | 17.3M |
| Depreciation and amortization | 5.0K | |||||
| EBIT | (12.5M) | (18.2M) | ||||
| EBIT margin, % | -624550.0% | -605566.7% | ||||
| Interest income | 2.0K | 3.0K | 47.0K | |||
| Net Income | (12.5M) | (18.2M) | (27.7M) | (32.5M) | (29.2M) | (17.3M) |